An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy

Trial Profile

An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs MTX 110 (Primary)
  • Indications Glioma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 25 May 2018 Status changed from planning to recruiting, according to a Midatech Pharma US media release.
    • 25 May 2018 According to a Midatech Pharma US media release, the company has commenced dosing in this trial. The Phase I safety component of the study is expected to read out in the second half of 2019 and the Phase II efficacy component is expected to read out in 2020.
    • 17 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top